April 2018 Br J Cardiol 2018;25:69–72 doi:10.5837/bjc.2018.011
Noman Ali, Haqeel A Jamil, Mohammad Waleed, Osama Raheem, Peysh Patel, Paul Sainsbury, Christopher Morley
Abstract
Introduction
Angina pectoris is the most common symptomatic manifestation of ischaemic heart disease (IHD), and is usually caused by an imbalance between myocardial oxygen supply and demand. Standard therapy for angina pectoris includes pharmacological agents, such as rate-limiting drugs and vasodilators. When symptoms are not satisfactorily controlled by pharmacotherapy alone, revascularisation via either percutaneous coronary intervention (PCI) or coronary artery bypass grafting (CABG) has been demonstrated to be of benefit in certain circumstances.1,2
While the majority of patients with angina pectoris can be managed successfully using a s
|
Full text
